We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

12 hedge funds and large institutions have $709K invested in MAIA Biotechnology in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,666% more capital inflows, than outflows

Capital inflows: $707K | Capital outflows: $40K

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more funds holding

Funds holding: 6 → 12 (+6)

1.71% more ownership

Funds ownership: 0.65% → 2.36% (+1.7%)

Holders
12
Holders Change
+6
Holders Change %
+100%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$250K
2
Lynwood Capital Management
Lynwood Capital Management
Ontario, Canada
+$93.6K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$90.9K
4
Bridgeway Capital Management
Bridgeway Capital Management
Texas
+$71.2K
5
Centric Wealth Management
Centric Wealth Management
Illinois
+$64.9K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$26.3K
2
UBS Group
UBS Group
Switzerland
-$13.7K

MAIA Hedge Fund Activity: Q2 2023 in Review

12 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q2 2023, worth a combined $709K — up 187% from $247K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MAIA positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $250K. The largest seller was Renaissance Technologies, cutting an estimated $26.3K.

  • 12 institutional investors held MAIA Biotechnology (MAIA) as of Q2 2023, up from 6 in Q1 2023.
  • Funds reported $709K of MAIA Biotechnology stock for Q2 2023, up 187% quarter-over-quarter.
  • 7 funds opened new MAIA Biotechnology positions in Q2 2023 and 1 closed out, a net change of +6 holders.
  • The largest MAIA Biotechnology buyer in Q2 2023 was Vanguard Group, an estimated $250K added.
  • The largest MAIA Biotechnology seller in Q2 2023 was Renaissance Technologies, an estimated $26.3K sold.

Based on aggregated 13F filings for Q2 2023.